Funding agencies: This work was supported by the Swedish Research Council (K2009-65X-15424-05-3, K2011-62X-21857-01-6, K2011-62X-21710-01-1), the Swedish federal government under the LUA/ALF agreement, the Swedish Alzheimer Foundation, the Foundations of the National Board of Health and Welfare, the Torsten and Ragnar Soderberg Foundation, the Clas Groschinsky Foundation, the Arosenius Foundation, the A ˚ ke Wiberg Foundation, the Jeansson Foundation, the Tore Nilsson Foundation for Medical Research, the Magnus Bergvall Foundation, and the Wilhelm and Martina Lundgren Science Foundation.
The glial marker YKL-40 is decreased in synucleinopathies
Article first published online: 11 JUL 2013
© 2013 Movement Disorder Society
Volume 28, Issue 13, pages 1882–1885, November 2013
How to Cite
Olsson, B., Constantinescu, R., Holmberg, B., Andreasen, N., Blennow, K. and Zetterberg, H. (2013), The glial marker YKL-40 is decreased in synucleinopathies. Mov. Disord., 28: 1882–1885. doi: 10.1002/mds.25589
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 13 NOV 2013
- Article first published online: 11 JUL 2013
- Manuscript Accepted: 29 MAY 2013
- Manuscript Revised: 3 MAY 2013
- Manuscript Received: 4 JAN 2013
- Parkinson's disease;
- parkinsonian disorders;
- cerebrospinal fluid;
Microglia are resident immunosurveillant cells in the central nervous system, and astrocytes are important for blood flow, plasticity, and neurotransmitter regulation. The aim of this study was to investigate whether astrocyte and microglial activation, estimated through markers in cerebrospinal fluid and serum, differed between synucleinopathies, tauopathies, and controls.
We analyzed the glial activation markers YKL-40 and soluble CD14 in serum and cerebrospinal fluid from 37 controls, 50 patients with Parkinson's disease (PD), and 79 P+ patients (those with progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy).
Cerebrospinal fluid levels of YKL-40 were decreased significantly in patients who had PD compared with controls (P < 0.05), patients who had multiple system atrophy (P < 0.01), and patients who had tauopathies (P < 0.0001). In addition, cerebrospinal fluid levels of YKL-40 were significantly lower in patients who had synucleinopathies than in those who had tauopathies (P < 0.0001).
The decreased cerebrospinal fluid levels of YKL-40 suggest that glial activation is reduced in the brains of patients who have Parkinson's disease and synucleinopathies compared with patients who have tauopathies and controls. © 2013 International Parkinson and Movement Disorder Society